Epstein-Barr Virus LMP-1 Natural Sequence Variants Differ in Their Potential To Activate Cellular Signaling Pathways
Open Access
- 1 October 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (19) , 9129-9141
- https://doi.org/10.1128/jvi.75.19.9129-9141.2001
Abstract
The latent membrane protein 1 (LMP-1) oncogene of Epstein-Barr virus (EBV) is believed to contribute to the development of many EBV-associated tumors, and there is evidence that sequence variation can affect some functions of LMP-1. Most studies have been restricted to the prototype B95.8 LMP-1 gene and genes isolated from EBV of nasopharyngeal carcinoma (NPC) patients. Here, we analyzed the signaling functions of LMP-1 from a panel of nine EBV isolates, including representatives of four defined groups of European LMP-1 variants (groups A to D [K. Sandvej, J. W. Gratama, M. Munch, X. G. Zhou, R. L. Bolhuis, B. S. Andresen, N. Gregersen, and S. Hamilton-Dutoit, Blood 90:323–330, 1997]) and Chinese NPC-derived LMP-1. Chinese and group D variants activated the transcription factor NF-κB two- to threefold more efficiently than B95.8 LMP-1, while Chinese, group B, and group D variants similarly activated activator protein 1 (AP-1) transcription more efficiently than did B95.8 LMP-1. However, there were no amino acid substitutions in the core binding regions for tumor necrosis factor receptor-associated adapter proteins known to mediate NF-κB and AP-1 activation. In contrast, despite sequence variation in the proposed Janus kinase 3 binding region, STAT activation was remarkably constant among the panel of LMP-1 variants. Analysis of the induction of CD54 (intercellular adhesion molecule 1) protein expression by the LMP-1 variants showed differences that did not correlate with either NF-κB or AP-1. Therefore, while the defined sequence variant groups do correlate with LMP-1 function, the results highlight the fact that the relationship between sequence variation and signaling function is extremely complex. It appears unlikely that one particular amino acid substitution or deletion will define a disease-associated variant of LMP-1.Keywords
This publication has 111 references indexed in Scilit:
- Mechanism of Action of a Novel Latent Membrane Protein-1 Dominant NegativePublished by Elsevier ,2001
- Characterization of Intercellular Adhesion Molecule-1 Regulation by Epstein-Barr Virus-encoded Latent Membrane Protein-1 Identifies Pathways That Cooperate with Nuclear Factor κB to Activate TranscriptionJournal of Biological Chemistry, 2001
- Epstein–Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regionsOncogene, 1998
- Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling MotifsJournal of Biological Chemistry, 1997
- Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1Oncogene, 1997
- Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomasEuropean Journal Of Cancer, 1995
- Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologueEuropean Journal Of Cancer, 1994
- Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell deathCell, 1991
- Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative DiseaseNew England Journal of Medicine, 1989
- An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cellsCell, 1985